See more : Privi Speciality Chemicals Limited (PRIVISCL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Alaunos Therapeutics, Inc. (TCRT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Alaunos Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Kiwi Technology Inc. (6699.TWO) Income Statement Analysis – Financial Results
- EuroSite Power Inc. (EUSP) Income Statement Analysis – Financial Results
- Digital360 S.p.A. (DIG.MI) Income Statement Analysis – Financial Results
- Blue Safari Group Acquisition Corp. (BSGAR) Income Statement Analysis – Financial Results
- Zhejiang HangKe Technology Incorporated Company (688006.SS) Income Statement Analysis – Financial Results
Alaunos Therapeutics, Inc. (TCRT)
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.00K | 2.92M | 398.00K | 0.00 | 0.00 | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Cost of Revenue | 4.80M | 2.76M | 740.00K | 1.13M | 629.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -4.80M | 163.00K | -342.00K | -1.13M | -629.00K | 146.00K | 6.39M | 6.86M | 4.33M | 1.37M | 800.00K | 800.00K | 667.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.57K | 1.73K |
| Gross Profit Ratio | -95,960.00% | 5.58% | -85.93% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 16.28M | 25.02M | 49.64M | 52.70M | 38.33M | 34.13M | 45.08M | 157.79M | 106.79M | 32.71M | 42.85M | 83.45M | 57.08M | 12.91M | 4.56M | 17.25M | 18.99M | 10.39M | 5.59M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 773.14K | 8.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 120.00 |
| SG&A | 12.22M | 13.14M | 27.56M | 27.67M | 19.53M | 19.92M | 14.80M | 14.38M | 17.65M | 12.17M | 15.66M | 19.52M | 14.98M | 11.64M | 7.57M | 8.37M | 9.58M | 8.72M | 4.19M | 39.17K | 35.36K | 0.00 | 120.00 |
| Other Expenses | 971.00K | 529.00K | -1.20M | 385.00K | 813.00K | 631.00K | 465.00K | 134.00K | 12.00K | -5.00K | -579.00K | -13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.39M | 0.00 | 0.00 | 486.00 | 42.51K | 74.14K |
| Operating Expenses | 29.47M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Cost & Expenses | 34.27M | 38.16M | 77.21M | 80.36M | 57.86M | 54.05M | 59.88M | 172.17M | 124.43M | 44.87M | 58.51M | 102.97M | 72.07M | 24.55M | 12.12M | 25.62M | 28.57M | 19.11M | 9.79M | 39.17K | 35.84K | 42.51K | 74.26K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.92M | 3.15M | 1.18M | 0.00 | 0.00 | 0.00 | 830.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.12M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.32M | 2.76M | 2.60M | 1.13M | 629.00K | 573.00K | 369.00K | 290.00K | 357.00K | 462.00K | 738.00K | 658.00K | 268.00K | 188.00K | 330.00K | 388.00K | 433.35K | 173.92K | 101.23K | 0.00 | 486.00 | 799.00 | 750.00 |
| EBITDA | -30.90M | -31.82M | -74.97M | -78.85M | -117.17M | -53.33M | -53.12M | -165.01M | -119.73M | -43.50M | -56.98M | -102.17M | -71.40M | -32.48M | -7.32M | -24.84M | -26.17M | -17.68M | -9.42M | -5.65M | -35.36K | -39.14K | -71.79K |
| EBITDA Ratio | -618,080.00% | -1,187.85% | -19,112.81% | 0.00% | 0.00% | -37,030.14% | -817.00% | -2,407.56% | -2,772.39% | -4,022.00% | -7,270.00% | -13,445.13% | -11,807.20% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,523.04% | -4,159.04% |
| Operating Income | -34.27M | -35.11M | -77.55M | -80.36M | 2.26M | -53.91M | -53.49M | -165.31M | -120.10M | -43.50M | -57.71M | -102.17M | -71.40M | -24.55M | -12.12M | -25.62M | -28.57M | -19.11M | -9.79M | -39.17K | -35.84K | -39.94K | -72.54K |
| Operating Income Ratio | -685,340.00% | -1,201.40% | -19,484.67% | 0.00% | 0.00% | -36,921.92% | -837.27% | -2,409.37% | -2,772.39% | -3,168.17% | -7,214.13% | -12,771.13% | -10,704.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Total Other Income/Expenses | -873.00K | -2.63M | -1.20M | 385.00K | -59.94M | 789.00K | -830.00K | 10.00K | 12.00K | 11.72M | 606.00K | 6.04M | 7.62M | -8.12M | 4.47M | 388.00K | 1.96M | 1.25M | 270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -35.14M | -37.73M | -78.75M | -79.98M | -117.80M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | 0.00 | -17.86M | 0.00 | -39.17K | -35.84K | -39.94K | -72.54K |
| Income Before Tax Ratio | -702,800.00% | -1,291.24% | -19,786.68% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| Income Tax Expense | 0.00 | -133.00K | -1.86M | -1.13M | 60.12M | -947.00K | 2.13M | 114.00K | -12.00K | -23.44M | -1.79M | -12.09M | -15.24M | 16.25M | -8.95M | -388.00K | -1.96M | -1.25M | -270.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -35.14M | -37.60M | -76.89M | -78.85M | -177.92M | -53.12M | -54.32M | -165.30M | -120.09M | -31.78M | -57.11M | -96.13M | -63.78M | -32.67M | -7.65M | -25.23M | -26.61M | -17.86M | -9.52M | -39.17K | -35.84K | -39.94K | -72.54K |
| Net Income Ratio | -702,800.00% | -1,286.69% | -19,320.10% | 0.00% | 0.00% | -36,381.51% | -850.26% | -2,409.23% | -2,772.11% | -2,314.71% | -7,138.38% | -12,016.50% | -9,561.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -1,554.12% | -4,202.49% |
| EPS | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.52 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| EPS Diluted | -21.97 | -25.97 | -53.80 | -56.42 | -158.90 | -55.44 | -59.50 | -190.15 | -143.63 | -47.14 | -99.67 | -183.58 | -144.94 | -106.52 | -49.65 | -178.25 | -211.94 | -213.06 | -262.83 | -39.44 | -18.31 | -26.73 | -48.55 |
| Weighted Avg Shares Out | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 956.72K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
| Weighted Avg Shares Out (Dil) | 1.60M | 1.45M | 1.43M | 1.40M | 1.12M | 958.07K | 912.92K | 869.28K | 836.11K | 674.20K | 572.95K | 523.64K | 440.03K | 306.69K | 154.05K | 141.55K | 125.55K | 83.81K | 36.21K | 993.00 | 1.96K | 1.49K | 1.49K |
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
Alaunos Therapeutics Still Waiting For Home Run
First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete response rates.
New Strong Buy Stocks for November 18th
VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.
Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive Officer Abhi Srivastava - Vice President, Technical Operations Drew Deniger...
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Company's human neoantigen T-cell receptor platform (hunTR) to...
Hot Penny Stocks To Watch As The Stock Market Crash Continues
Hot penny stocks to add to your watch list this week. Is it time to buy?
Hot Penny Stocks To Watch Today As Stock Market Crash Continues
Hot penny stocks to watch today. The post Hot Penny Stocks To Watch Today As Stock Market Crash Continues appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Making Money With Penny Stocks When the Market Crashes
How to make money with penny stocks during a market crash The post Making Money With Penny Stocks When the Market Crashes appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Alaunos Therapeutics Stock Is Soaring Today
The biotech is rebounding after yesterday's big sell-off.
Alaunos Therapeutics - T-Cell Therapies
100% technical buy signals. 10 new highs and up 105.45% in the last month.
Source: https://incomestatements.info
Category: Stock Reports